• Learn about TTR-FAP, a type of transthyretin amyloidosis

  • See the impact of TTR-FAP on patients' lives

  • Learn about diagnosis and
    patient management

The THAOS (Transthyretin Amyloidosis Outcomes Survey)
Registry: a global resource for TTR-FAP

THAOS is a 10-year, longitudinal, observational disease registry open to all clinicians treating patients with transthyretin-associated amyloidosis.

The objectives of THAOS are to:

  • Enhance the understanding of disease natural history, including the variability and progression of the hereditary and acquired forms of the disease
  • Better understand the genotype-phenotype relationship in transthyretin amyloidosis
  • Compare the progression of disease and overall survival in patients with transthyretin amyloidosis with and without liver transplant
  • Evaluate treatment modalities that may benefit patients with TTR amyloidosis
  • Foster an international community of medical experts who will develop recommendations on the clinical management of patients with transthyretin amyloidosis

Financial support for the THAOS Registry has been provided by Pfizer. The THAOS Registry is overseen by a scientific board composed of scientific and clinical experts in the field of amyloid disease, including Pfizer representation. Pfizer is the legal owner of all survey data and may use the data for purposes including regulatory submissions.

Visit the THAOS Web site Download the THAOS brochure